438050-33-0Relevant academic research and scientific papers
Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
Christopher, John A.,Aves, Sarah J.,Brown, Jason,Errey, James C.,Klair, Suki S.,Langmead, Christopher J.,Mace, Oliver J.,Mould, Richard,Patel, Jayesh C.,Tehan, Benjamin G.,Zhukov, Andrei,Marshall, Fiona H.,Congreve, Miles
supporting information, p. 947 - 955 (2015/05/27)
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parame
OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 82-83, (2014/01/18)
The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
Novel piperazine derivatives
-
, (2008/06/13)
The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.
